Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

0.8420 -0.0280 (-3.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers traders will want to know about on Wednesday morning! 
Via InvestorPlace
Why iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) jumped 119.6% to $1.96 in pre-market trading. HeartCore forged an agreement with rYojbaba Inc for its tenth Go IPO consulting service win. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday as we dive into all of the latest news affecting markets this morning. 
Via InvestorPlace
Why Kalera Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 164% to $3.86 after the company announced it launched ChatGPT-enabled smart eyewear. 
Via Benzinga
Why Is Virgin Orbit (VORB) Stock Down 27% Today?
Virgin Orbit (VORB) stock is falling on Tuesday after the space travel company received a delisting notice from the Nasdaq Exchange. 
Via InvestorPlace
Why Is PLx Pharma (PLXP) Stock Down 38% Today?
PLx Pharma (PLXP) stock is taking a beating on Tuesday and there's a couple of reasons investors will want to know about its fall. 
Via InvestorPlace
Why Is Clearmind Medicine (CMND) Stock Up 56% Today?
Clearmind Medicine (CMND) stock is taking off on Tuesday with heavy trading despite a lack of news concerning the psychedelics company. 
Via InvestorPlace
Why National CineMedia Shares Are Trading Higher By Around 111%; Here Are 20 Stocks Moving Premarket
Gainers National CineMedia, Inc. (NASDAQ: NCMI) jumped 111.2% to $0.2810 in pre-market trading after a 13G filing showed a 9.1% passive stake in the company from AMC Entertainment. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on Tuesday! 
Via InvestorPlace
How To Finance A Psychedelics Business? Learn From These Four Companies
Clearmind Medicine Announces Pricing of $3.5 Million Public Offering 
Via Benzinga
Dow Tumbles Over 200 Points; Butterfly Network Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 200 points on Tuesday. The Dow traded down 0.64% to 33,387.61 while the NASDAQ fell 0.45% to 12,134.09. The S&P... 
Via Benzinga
Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43. 
Via Benzinga
Gold Rises Sharply; AMC Entertainment Shares Plunge
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 150 points on Tuesday. The Dow traded down 0.46% to 33,447.10 while the NASDAQ fell 0.30% to 12,152.44. The S&P 500,... 
Via Benzinga
Why Clearmind Medicine Shares Are Nosediving
Clearmind Medicine Inc (NASDAQ: CMND) shares are trading lower by 60.1% to $0.57 Tuesday morning after the company announced a $3.5 million public offering priced at $0.78 per share. The offering is... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers for Tuesday morning with all the latest news traders need to know about! 
Via InvestorPlace
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
A Drug That Mimics Alcohol Buzz Is Bound For Human Trials: Here's What's Next
Israeli biotech Clearmind Medicine Inc. (NASDAQ: CMND) has submitted an Investigational New Drug (IND) application with the FDA towards approval to commence its first-in-human Phase 1/2a clinical trial... 
Via Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash. 
Via Benzinga
US Stocks Mostly Higher; Dow Rises 75 Points
U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 75 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 31,986.55 while the NASDAQ rose... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday! 
Via InvestorPlace
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
SciSparc And Clearmind Reveal Three Unique Combinations Of Future Psychedelic-Based Compounds
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its... 
Via Benzinga
Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US
Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications... 
Via Benzinga
EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead
(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction 
Via Benzinga
Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results
Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained... 
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday! 
Via InvestorPlace
EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When
(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction 
Via Benzinga
EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains
(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.